Quantcast
Last updated on April 16, 2014 at 10:49 EDT

Latest Formoterol Stories

2013-11-11 08:28:31

Resources Available to Help Take Control WILMINGTON, Del., Nov. 11, 2013 /PRNewswire/ -- For many Americans, breathing is a challenge. Over 12 million have chronic obstructive pulmonary disease (COPD)( )and live with symptoms, including constant coughing, wheezing, and shortness of breath. But with an additional 12 million Americans remaining undiagnosed, recognizing COPD signs and symptoms and seeking help is an important health priority. To view the multimedia assets associated with this...

2013-06-17 08:28:01

MISSISSAUGA, ON, June 17, 2013 /CNW/ - A second analysis of data from real-world study PATHOS, recently published in the British Medical Journal, shows that treatment of chronic obstructive pulmonary disease (COPD) patients with SYMBICORT(®) (budesonide/formoterol) was associated with a lower incidence of pneumonia and pneumonia related death, compared to treatment of COPD patients with ADVAIR(®) (fluticasone/salmeterol).(i) PATHOS is the largest real-world study to compare the...

2013-06-06 08:29:51

TEL AVIV, Israel, June 6, 2013 /PRNewswire/ -- Inspiro Medical [http://www.inspiromedical.com ], a portfolio company of The Trendlines Group, recently completed a successful clinical trial for InspiromaticTM, its innovative, breath-synchronized, active dry powder inhaler. The study, completed in May 2013 at Schneider Medical Center aimed to objectively assess, in a randomized, crossover, double blind study, the efficacy and safety profiles of formoterol (bronchodilator)...

2013-05-13 16:27:10

WILMINGTON, Del., May 13, 2013 /PRNewswire/ -- Approximately 25 million Americans suffer from asthma, which accounts for more than 3300 deaths each year. AstraZeneca (NYSE: AZN) is urging Americans to embrace National Asthma & Allergy Awareness Month this May by taking proactive steps to gain control of their asthma and learn more about how it may be impacting their lives. To view the multimedia assets associated with this release, please click:...

2013-03-22 08:24:45

MISSISSAUGA, ON, March 22, 2013 /CNW/ - PATHOS is the largest real-world study to compare the effectiveness of two commonly prescribed inhaled corticosteroid and long-acting beta agonist (ICS/LABA) combination treatments for chronic obstructive pulmonary disease (COPD) with more than one year of patient follow-up.(1 )An analysis of PATHOS data shows that COPD patients treated with SYMBICORT(®) (budesonide/formoterol) are significantly less likely to suffer from COPD-related...

2012-10-24 07:30:29

REDWOOD CITY, Calif., Oct. 24, 2012 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the completion of the Company's randomized, double-blind, dose-ranging Phase 2b trial of PT003, Pearl's lead investigational inhaled combination bronchodilator product for the treatment of patients with moderate-to-severe COPD. This study assessed five BID doses of PT003, in which formoterol fumarate (FF) was co-formulated with five descending doses of glycopyrrolate (GP) and administered via...

2012-09-13 02:27:56

REDWOOD CITY, Calif., Sept. 13, 2012 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the completion of a randomized, double-blind Phase 2b dose-ranging study in which six doses of the long-acting muscarinic antagonist (LAMA), glycopyrrolate (GP) ranging from 18 micrograms to 600 nanograms BID were delivered via metered-dose inhaler (GP MDI; PT001) to patients with moderate-to-severe COPD. In this study (NCT01566773) and the previously conducted dose-ranging GP MDI studies, a total of...

2012-05-31 02:26:36

NEW YORK, May 31, 2012 /PRNewswire/ -- Citeline, the world's leading research authority on pharmaceutical clinical trials, updates, and intelligence recently reviewed the results presented at the American Thoracic Society (ATS) conference held May 18-23, 2012 in San Francisco, CA. The strong competition to launch the next fixed dose combination (FDC) blockbuster for chronic obstructive pulmonary disease (COPD) was of particular interest to reviewer Jennifer Stacey, Citeline's Analyst in...

2012-05-14 06:27:07

In the news release, Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD, issued 14-May-2012 by Pearl Therapeutics over PR Newswire, we are advised by the company that the dateline date should read "May 14, 2012" rather than "May 14, 2011" as originally issued inadvertently. The complete, corrected release follows: Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients...

2012-05-14 02:27:37

REDWOOD CITY, Calif., May 14, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist (LABA). PT003 and its components, PT001 (GP MDI) and PT005 (FF MDI) are being developed for the...